WASHINGTON, D.C., Aug. 08, 2018 (GLOBE NEWSWIRE) — The Alliance for Regenerative Medicine (ARM) today released its most recent quarterly data report, offering an in-depth look at cell therapy, gene therapy, tissue engineering and broader global regenerative medicine sector trends and metrics in the second quarter and first half of 2018.
By further curating information provided by ARM’s data partner Informa, the quarterly data report details industry-specific statistics compiled from more than 875 cell therapy, gene therapy, tissue engineering, and other regenerative medicine companies worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events and current legislative and regulatory priorities.
The Q2 2018 data report also features commentary from ARM’s recent webinar on the RMAT designation, cohosted with Informa. The commentary includes insights from Michael Werner, ARM co-Founder and Senior Policy Counsel; Kevin Healy, Global Regulatory Lead at Roivant Sciences, representing Enzyvant Therapeutics; Gil Van Bokkelen, CEO of Athersys; and Tim Miller, President and Chief Scientific Officer at Abeona Therapeutics. The report also includes a brief comparison of the RMAT designation and the Breakthrough Therapy designation, provided by Amanda Micklus, Principal Analyst at Pharma Intelligence at Informa.
“There has been a tremendous amount of forward momentum during the first half of this year, both clinically and commercially,” said Janet Lynch Lambert, ARM’s Chief Executive Officer. “We’re excited for the continued growth of the regenerative medicine sector, and what it means for patients worldwide.”
Highlighted findings from the Q2 2018 data report include:
- Globally, companies active in gene and cellular therapies and other regenerative medicines raised more than $4.1 billion in the second quarter of 2018, a 164% increase from Q2 2017. The report also includes financial data broken out by technology type and financing type.
- There were 977 clinical trials underway worldwide at the close of the second quarter of 2018, with more than 54 percent of those in oncology and nearly 10 percent in cardiovascular disorders. The report also includes figures on clinical trials by phase and indication, as well as by technology type.
ARM will continue to update this information through new reports to be released after the close of each quarter, tracking sector performance, key financial information, clinical trial numbers, and clinical data events.
For more information, please visit www.alliancerm.org or contact Lyndsey Scull at firstname.lastname@example.org.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 300 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.
CONTACT: The Alliance for Regenerative Medicine Lyndsey Scull 202 213 7086 email@example.com